37 citations,
March 2010 in “British Journal of Dermatology”
Oestrogen and thyrotropin-releasing hormone affect prolactin and its receptor in human skin and hair, suggesting new treatment options for related conditions.
The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactinreceptor inhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.
The conversation is about finding the optimal concentration of topical melatonin for hair loss treatment. The user is considering making their own solution and is unsure whether a higher concentration is more effective for deactivating prolactinreceptors.
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactinreceptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.